Equities analysts expect that Opko Health, Inc. (NASDAQ:OPK) will report earnings of ($0.08) per share for the current quarter, according to Zacks. Three analysts have made estimates for Opko Health’s earnings, with the lowest EPS estimate coming in at ($0.10) and the highest estimate coming in at ($0.05). Opko Health posted earnings of ($0.04) per share during the same quarter last year, which would suggest a negative year over year growth rate of 100%. The business is scheduled to report its next earnings results on Wednesday, March 7th.
On average, analysts expect that Opko Health will report full year earnings of ($0.27) per share for the current year, with EPS estimates ranging from ($0.34) to ($0.22). For the next fiscal year, analysts anticipate that the firm will report earnings of ($0.17) per share, with EPS estimates ranging from ($0.24) to ($0.06). Zacks Investment Research’s EPS calculations are a mean average based on a survey of sell-side research firms that follow Opko Health.
Opko Health (NASDAQ:OPK) last issued its earnings results on Wednesday, November 8th. The biotechnology company reported ($0.08) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.05) by ($0.03). The business had revenue of $263.50 million for the quarter, compared to analyst estimates of $319.43 million. Opko Health had a negative return on equity of 5.17% and a negative net margin of 9.45%. The firm’s revenue was down 11.6% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.03) EPS.
Several research analysts have recently issued reports on OPK shares. BidaskClub downgraded Opko Health from a “hold” rating to a “sell” rating in a research note on Tuesday, August 1st. Jefferies Group LLC reissued a “hold” rating and set a $6.50 target price (down previously from $6.80) on shares of Opko Health in a research report on Thursday, August 10th. Cantor Fitzgerald initiated coverage on shares of Opko Health in a research report on Thursday, August 17th. They set an “overweight” rating and a $20.00 target price for the company. Ladenburg Thalmann Financial Services reissued a “buy” rating and set a $16.00 target price on shares of Opko Health in a research report on Monday, September 25th. Finally, Zacks Investment Research raised shares of Opko Health from a “sell” rating to a “hold” rating in a research report on Thursday, October 26th. Two analysts have rated the stock with a sell rating, two have given a hold rating and six have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average price target of $13.97.
Opko Health (NASDAQ:OPK) opened at $4.94 on Monday. Opko Health has a 52 week low of $4.50 and a 52 week high of $12.15. The company has a current ratio of 1.66, a quick ratio of 1.48 and a debt-to-equity ratio of 0.01.
TRADEMARK VIOLATION NOTICE: “Opko Health, Inc. (OPK) Expected to Announce Earnings of -$0.08 Per Share” was first posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this report on another publication, it was stolen and reposted in violation of international trademark & copyright legislation. The correct version of this report can be viewed at https://www.dispatchtribunal.com/2017/12/05/opko-health-inc-opk-expected-to-announce-earnings-of-0-08-per-share.html.
In other Opko Health news, major shareholder Opko Health, Inc. bought 655,738 shares of the firm’s stock in a transaction dated Monday, October 30th. The stock was purchased at an average cost of $3.05 per share, with a total value of $2,000,000.90. Following the transaction, the insider now directly owns 6,678,752 shares in the company, valued at approximately $20,370,193.60. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CEO Phillip Md Et Al Frost bought 10,000 shares of the firm’s stock in a transaction dated Thursday, August 24th. The shares were acquired at an average cost of $6.24 per share, with a total value of $62,400.00. Following the completion of the transaction, the chief executive officer now owns 3,068,951 shares in the company, valued at $19,150,254.24. The disclosure for this purchase can be found here. Over the last quarter, insiders purchased 1,101,038 shares of company stock worth $4,676,040. 40.19% of the stock is owned by company insiders.
Several institutional investors have recently made changes to their positions in the company. Teachers Advisors LLC increased its holdings in Opko Health by 3.0% in the 1st quarter. Teachers Advisors LLC now owns 405,251 shares of the biotechnology company’s stock worth $3,242,000 after acquiring an additional 11,782 shares during the last quarter. Legal & General Group Plc increased its holdings in Opko Health by 217.4% in the 1st quarter. Legal & General Group Plc now owns 111,673 shares of the biotechnology company’s stock worth $893,000 after acquiring an additional 76,487 shares during the last quarter. Dimensional Fund Advisors LP increased its holdings in Opko Health by 2.0% in the 1st quarter. Dimensional Fund Advisors LP now owns 1,621,128 shares of the biotechnology company’s stock worth $12,968,000 after acquiring an additional 31,225 shares during the last quarter. Fox Run Management L.L.C. purchased a new stake in Opko Health in the 2nd quarter worth about $176,000. Finally, Eqis Capital Management Inc. increased its holdings in Opko Health by 16.5% in the 2nd quarter. Eqis Capital Management Inc. now owns 39,781 shares of the biotechnology company’s stock worth $262,000 after acquiring an additional 5,622 shares during the last quarter. 22.33% of the stock is owned by hedge funds and other institutional investors.
About Opko Health
OPKO Health, Inc is a healthcare company. Its segments include Pharmaceutical, Diagnostics and Corporate. Pharmaceutical consists of the pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain and its pharmaceutical research and development operations. Diagnostics consists of the clinical laboratory operations in Bio-Reference Laboratories (Bio-Reference) and its point-of-care operations.
Get a free copy of the Zacks research report on Opko Health (OPK)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Opko Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.